Organic Active Ingredients TRIZ Cases

Co-administering a soluble prodrug with its converting enzyme creates supersaturated drug concentrations that rapidly cross mucosal membranes.

Maleate salt of pritelivir resolves physico-chemical stability issues found in mesylate forms while maintaining antiviral activity.

Palmitoyl dipeptide-5 and phytosphingosine promote vascular endothelial growth factor expression in dermal papilla cells to enhance hair shaft elongation.

5-HT1B receptor agonists sustain muscle regeneration by preventing satellite cell pool exhaustion during repeated injury cycles.

Using 200 to 230 nm ultraviolet irradiation combined with topical amino acids eliminates odor generation and mitigates skin damage risks.

A plant extract mixture comprising Chrysanthellum, artichoke, blueberry, and olive extracts addresses chronic inflammatory bowel disease symptoms.

A genetically modified system manipulates Schwann cell functions to treat dysfunction disorders.

Formula I capsid inhibitors suppress viral replication while reducing long-term toxicities and resistance emergence.

Compounds of formula I bind untranslated RNA to reduce BMI-1 expression, overcoming the lack of effective agents for treating cancer.

Aminothiazolopyrimidinedione derivatives activate TLR7 and TLR8, resolving efficacy and safety trade-offs in antiviral treatments.

Benzimidazole derivatives inhibit RET and VEGFR2 kinases by binding ATP sites to block cell proliferation.

Non-nucleotide chemical linkers fuse crgRNA and tracrgRNA modules to stabilize complexes against degradation while minimizing off-target cleavage effects.

Crystalline neurotrophin mimetic compounds provide targeted modulation of p75 NTR receptors to prevent cellular degeneration.

15-PGDH inhibitors increase tissue prostaglandin levels to promote wound healing and hair growth.

Formula IA and IB compounds stimulate soluble guanylate cyclase to increase cyclic GMP levels.

Deuterium substitution slows oxidative metabolism to extend half-life and reduce interpatient variability.

A metal-salen complex compound crosses the blood-brain barrier to reach brain tumor tissues.

Mono-substituted indole compounds inhibit dengue viral replication, addressing the lack of broad-spectrum antiviral drugs for all four serotypes.

Segmenting prostaglandin signaling via selective EP2 and EP4 antagonism avoids cardiovascular toxicity linked to broad COX-2 inhibition.

Segmented gapmer compounds with modified sugar backbones lower triglyceride and cholesterol concentrations to treat cardiometabolic diseases.

L-ergothioneine bypasses peptidase degradation of oral supplements by serving as a mediator that increases glutathione levels.

Segmented tetrahydroisoquinoline structures balance therapeutic efficacy with manufacturability while activating Nrf2 to mitigate oxidative damage.

A transdermal adhesive formulation process replaces ester solvents with non-reactive organic alternatives to enhance active ingredient availability.

Crystalline forms of Compound 1 improve therapeutic efficacy for SK2 channel-related diseases while managing manufacturing complexity.

Biodegradable inhalable microparticles deliver antitubercular drugs to lung macrophages, bypassing rapid plasma clearance and systemic toxicity.

Novel Lesinurad crystalline forms enhance solubility and stability, resolving hygroscopicity and toxic solvent residue issues in pharmaceutical manufacturing.

Sildenafil modulates cGMP signaling pathways to repair brain and retinal injuries caused by oxygen exposure in newborns.

Cyclodextrins and antioxidants stabilize dexamethasone sodium phosphate in aqueous solutions, extending shelf life without restrictive storage conditions.

Novel mutations stabilize prefusion SARS-CoV-2 spike protein conformations on yeast surfaces.

Engineered cytochrome P450 enzymes replace complex chemical routes to selectively produce cis stereoisomers, resolving low yield and instability issues.

Local FK506 delivery via fibrin gel sustains axon regeneration while preventing systemic toxicity from kidney damage and immunosuppression.

Ethyl ester prodrug improves oral bioavailability of nep inhibitor while maintaining thermal stability.

GD3S inhibitors block enzyme activity to prevent tumor relapse from resistant stem cell populations.

Delta12-prostaglandin J3 eradicates refractory leukemia stem cells by activating the p53 apoptotic pathway, restoring normal hematological parameters.

Single formulation merges multiple active ingredients to reduce supplementation complexity while achieving synergistic efficacy for cervical tissue.

A solid dosage form uses asymmetric geometry and surface ridges to reduce the contact patch area against bodily surfaces.

FLT3 receptor antagonists alleviate thermal and mechanical hyperalgesia by blocking the interaction between the FLT3 receptor and its ligand.

Replacing surgical procedures, this topical formulation treats cervical dysplasia by inducing apoptosis in HPV-infected cells without invasive morbidities.

A low molecular weight pyrazoloquinazoline compound inhibits cyclin-dependent kinases to suppress glioma proliferation.

Anhydrous polymorphic form II of sodium hyodeoxycholate achieves high chemical purity through controlled crystallization kinetics.

Formula I compounds resolve specificity limits by inducing targeted antiviral cytokines.

Antisense oligonucleotides hybridize to STAT3 mRNA to inhibit expression, avoiding off-target effects on other STAT isoforms.

Liposomal CoQ10 bypasses hepatic accumulation to selectively inhibit tumor growth and angiogenesis without harming normal tissue.

Azido-diarylpyrimidines use UV light to create irreversible covalent bonds with reverse transcriptase, preventing viral enzyme escape and replication.

A pharmaceutical composition using miRNA inhibitors to target specific microRNAs for treating vascular smooth muscle cell proliferative diseases.

Optimized splice-switching oligonucleotides modulate AR pre-mRNA splicing to reduce constitutively active AR-V7 variant production.

Removing inorganic salts from phosphate buffered saline prevents aptamer multimerization. Mannitol maintains the monomeric state, preserving binding activity for long-term storage.

Short activating RNA targets antisense transcripts to induce glucose-responsive insulin production, avoiding viral safety risks.

Empagliflozin reduces oxidative stress via urinary glucose excretion, bypassing beta-cell decline to sustain glycemic control.

A multi-layer oral formulation protects fat soluble antioxidants using a thermo-sensitive polymer gel coating.

An isoxazole derivative compound inhibits mutant IDH1 protein activity.

Combines an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant to treat hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Fluorinated tetrahydronaphthyridinyl derivatives inhibit alpha v integrins, offering a universal treatment approach for multiple fibrotic conditions.

Bis-amide compounds block viral cytopathic effects, addressing the lack of effective treatments for severe acute respiratory syndrome.

Kombo butter acid extracts containing sargaquinoic acid reduce brain infarct volume, addressing limited efficacy of current thrombolytic therapies.

Formulations devoid of C-11+ fatty acids prevent fungal nutrient uptake while extending antifungal exposure time to reduce dandruff relapse.

An implanted biodegradable matrix releases dexamethasone continuously, resolving compliance issues from frequent injections while maintaining efficacy.

Non-polar siloxane solvent enables rapid drying of silicone resin films that adhere to body surfaces and release drugs over twelve hours without stinging.

Chimeric conjugates recruit E3 ligases to degrade viral proteases, overcoming partial inhibition limits.

99mTc-DTPA-nateglinide conjugates target beta-cell receptors, resolving the contradiction between precise functional imaging and acute toxicity risks.

Humanized anti-TNF antibodies SEQ ID NO:36 and 37 reduce immunogenicity while maintaining therapeutic efficacy in psoriatic arthritis.

Gene expression signatures detect antifolate response in cancer samples, resolving patient variability through biomarker segmentation.

Phospholipid liposomes maintain lubrication above phase transition temperatures, preventing cartilage degeneration under inflammatory conditions.

Fractionated CAR T cell dosing mitigates cytokine release syndrome and on-target off-tumor toxicities in solid tumor therapy.

Arginine and tannin combination promotes lactic acid bacteria proliferation, avoiding complex anaerobic culture operations required for bifidobacteria.

Active vitamin D metabolites downregulate inflammatory genes to mitigate cytokine storms and oxidative stress in acute respiratory distress syndrome.

Segmenting receptor targeting via a bivalent ligand reduces inflammatory pain without inducing tolerance or dependence.

Isotope-selective pharmaceutical composition transforms malignant phenotypes into normal cells using specific elemental isotopes.

Ester wax mediates between adhesive components and levonorgestrel to prevent oxidative degradation.

Fetal cardiac stromal cell exosomes deliver specific micro RNAs to address the lack of effective regenerative solutions in current cardiac therapies.

A blood storage composition containing arginine and ribose maintains cellular energy levels in red blood cells.

Melt processing solid pharmaceutical compositions using polyethylene glycol binder to achieve high drug load formulations.

Thiazolidinone compounds block anandamide membrane transport to increase extracellular levels without activating TRPV1 channels or inhibiting FAAH.

Chemerin inhibitors reduce metastatic potential by targeting specific molecular pathways, addressing limited treatment effectiveness in kidney cancer.

Polyanhydride matrices modulate z-butylidenephthalide diffusion to overcome blood-brain barrier obstruction and suppress glioblastoma growth.

Formula I indazole compounds inhibit FGFR and VEGFR kinases to resolve specificity and efficacy trade-offs in cancer treatment.

Targeted TGFβ receptor antagonists resolve the trade-off between broad pathway inhibition and precise receptor selectivity to treat proliferative disorders.

Non-naturally occurring modifications in TREMs enhance protein synthesis efficiency while maintaining cellular process stability.

Water-soluble chitosan derivatives permeate keratin structures in nail lacquers to deliver therapeutic agents directly to the nail matrix.

Triazole compounds induce oligodendrocyte precursor cell differentiation to repair demyelinated axons without suppressing the immune system.

Demethylating agents reverse viral genome methylation to restore antigen presentation and trigger T-cell responses against papillomavirus.

Specific inert nucleus sizing maintains inter-pellet homogeneity and dosification uniformity for sustained therapeutic efficacy.

Combines sotorasib with an anti-EGFR antibody to inhibit KRAS G12C tumors, addressing limited therapeutic options.

IKZF2-specific degraders lower regulatory T cell protein levels via local quality, resolving systemic toxicity while enhancing cancer treatment efficacy.

Poloxamer increases haemoglobin and red blood cell levels without the toxic side effects or cardiovascular risks associated with erythropoietin therapy.

Pyridazinone compounds inhibit PARP7 to activate T cell-mediated tumor killing and suppress PDL-1 expression.

Administering an O-glycnacylation modifier agent resolves inadequate blood vessel growth in critical limb ischemia by enhancing functional regeneration.

A hydrophobic prodrug isoxazoline derivative converts to an active caspase inhibitor via enzymatic action.

TACI-Fc fusion antagonists target BLyS and APRIL pathways to lower immunoglobulin levels in autoimmune disease treatment.

Double-stranded nucleic acids mediate RNA interference to degrade C3 mRNA, addressing limited patient response to existing complement therapies.

Substituted heterocycle fused gamma-carbolines provide rapid antidepressant onset without mu-opiate receptor activity or addiction risks.